Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213306 | 1.00 | ABCB1 (0.50) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL27810816 | 0.85 | ABCB1 (0.50) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL2729968 | 0.85 | ABCB1 (0.50) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL24733700 | 0.84 | ABCB1 (0.49) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL18675299 | 0.84 | ABCB1 (0.49) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL23879129 | 0.84 | ABCB1 (0.49) | ABCB1SYKALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL30863382 | 0.80 | ABCB1 (0.49) | ABCB1SYKALDH1A1L3MBTL1MAPT | |
| SCHEMBL8397216 | 0.79 | ABCB1 (0.48) | ABCB1SYKALDH1A1L3MBTL1MAPT | |
| SCHEMBL16284416 | 0.79 | ABCB1 (0.48) | ABCB1SYKALDH1A1L3MBTL1MAPT | |
| SCHEMBL28638619 | 0.79 | SYK (0.45) | SYKALDH1A1L3MBTL1MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. | 2017-03-16 | — | — | US | disclosed |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2016-10-13 | — | — | US | disclosed |
| US-9187524-B2 | Broad spectrum antibiotic arylomycin analogs | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | NAVY, SECRETARY OF THE UNITED STATES OF AMERICA | 2015-02-12 | — | — | US | disclosed |
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | ABCB1 1608/4885SYK 2120/4885ALDH1A1 1710/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | ABCB1 1608/4885SYK 2120/4885ALDH1A1 1710/4885 |
| US-20140249073-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | ABCB1 1561/4885SYK 2415/4885ALDH1A1 2541/4885 |
| US-20170073370-A1 | BROAD SPECTRUM ANTIBIOTICS | SPAST, NPEPPS, SPOUT1 | ABCB1 1561/4885SYK 2415/4885ALDH1A1 2541/4885 |
| US-20150045286-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | ABCB1 949/4885SYK 2653/4885ALDH1A1 3378/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | ABCB1 1608/4885SYK 2120/4885ALDH1A1 1710/4885 |
| US-20160297851-A1 | BROAD SPECTRUM ANTIBIOTIC ARYLOMYCIN ANALOGS | SPAST, NPEPPS, SPATS2L | ABCB1 949/4885SYK 2653/4885ALDH1A1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.